5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10.
about
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levelsKey Targets for Multi-Target Ligands Designed to Combat NeurodegenerationRegulation of amyloid precursor protein processing by serotonin signalingAPP as a Protective Factor in Acute Neuronal Insults.Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.The serotonergic system and cognitive functionEarly administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease.Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment.Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα.The Role of ADAM10 in Alzheimer's Disease.Developing BACE-1 inhibitors for FXS.Downregulation of ADAM10 expression inhibits metastasis and invasiveness of human hepatocellular carcinoma HepG2 cells.Non-amyloidogenic effects of α2 adrenergic agonists: implications for brimonidine-mediated neuroprotection.Serotoninergic antidepressants positively affect platelet ADAM10 expression in patients with Alzheimer's disease.Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.
P2860
Q26751302-C3E178CC-4DD8-43D1-A958-96F3769DF700Q28077589-E06F7674-565C-4556-8168-7C35B31A4127Q28538947-589062EC-D0F1-49E4-9A65-118001D39D4FQ34551487-FC89D4AF-87FC-4595-A017-4328C345723DQ34583429-208D19BA-2549-48D6-8760-27BC4DBD9606Q37245282-830C14CD-BB34-419D-9CD4-8B1475852294Q37412086-075BB16E-CF61-4CB8-99AA-C94F7BCC83F7Q38683808-3724DE32-1985-48DE-BEEC-68E207A2F09CQ38962792-933B5F00-CFBA-42A2-B84F-37E30A778E3DQ39145999-9BFBAF86-885A-4AE9-893C-AD5D46F7E8F2Q39242629-D72E14C8-5F2A-439E-882F-CBCA0E63E6B1Q41073215-6089FE04-9D4D-498E-AD07-8E01643BD53AQ42087031-7F4352F5-F76E-4864-8287-F9DBEDF72B81Q42328273-3AB9AB45-7E26-4018-926E-F28D5F017E4EQ48070770-38A291ED-1E36-4AF3-A7AE-BA167CFD9B0CQ52656382-971E42A1-89DE-4585-BF14-0D7ACC5AF860
P2860
5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
5-HT4 receptors constitutively ...... vage and interact with ADAM10.
@en
5-HT4 receptors constitutively ...... vage and interact with ADAM10.
@nl
type
label
5-HT4 receptors constitutively ...... vage and interact with ADAM10.
@en
5-HT4 receptors constitutively ...... vage and interact with ADAM10.
@nl
prefLabel
5-HT4 receptors constitutively ...... vage and interact with ADAM10.
@en
5-HT4 receptors constitutively ...... vage and interact with ADAM10.
@nl
P2093
P2860
P356
P1476
5-HT4 receptors constitutively ...... vage and interact with ADAM10.
@en
P2093
Aline Dumuis
Elisabeth Cassier
Florence Gaven
Joël Bockaert
Maud Cochet
Philippe Marin
Romain Donneger
P2860
P304
P356
10.1021/CN300095T
P577
2012-10-13T00:00:00Z